KLK3 and prostate carcinoma: When limited to early-stage prostate cancer cases (n = 8), PSA performance further deteriorated, with a sensitivity of 12.5%, specificity of 40.0%, AUC of 0.05, NPV of 22.2%, PPV of 25.0%, and ACC of 23.1%.